Study on relationship of Inflammatory Prognostic Scoring Index with treatment outcomes in patients with multiple myeloma
Main Article Content
Abstract
The relationship between IPSI and treatment outcomes in MM patients was examined at the Military Hospital 103 from January 2017 to April 2025. 71 patients diagnosed and treated at Military Hospital 103 were divided into three groups: IPSI 0-1: 21 patients; IPSI 2-3: 12 patients; and IPSI 4-5: 38 patients. There was a difference in the ISS staging system among the IPSI groups (p = 0.013). A complete response was observed in 81% of patients in the IPSI 0-1 group, which was higher than 75% in the IPSI 2-3 group and 42.1% in the IPSI 4-5 group (p = 0.035). The risk of death in the IPSI 4-5 group was 3.771 times higher, and in the IPSI 2-3 group was 2.070 times higher, compared to the IPSI 0-1 group. The overall survival (OS) of the IPSI 0-1 group was 69.7 months, which was longer than the OS of the IPSI 2-3 group (60.3 months) and the IPSI 4-5 group (30.2 months) (p = 0.045). IPSI is associated with the prognosis of newly diagnosed MM patients and may be a useful addition to the ISS staging system.
Article Details
Keywords
Multiple myeloma, Inflammatory Prognostic Scoring Index (IPSI), Military Hospital 103
References
2. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. Journal of clinical oncology. 2015;33(26):2863-2869.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646-674.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
5. Liu S, Shi J, Guo H, et al. Prognostic significance of the inflammatory index-based scoring system in patients preliminarily diagnosed with multiple myeloma in the bortezomib-based chemotherapy era. Cancer Management and Research. 2019:9409-9420.
6. Chengbin Z, Chunlian C. Study on predictive value of blood routine index in clinical staging and prognosis of newly diagnosed multiple myeloma. J Clin Hematol. 2021;34(10):723-727.
7. Li Y, Li H, Li W, et al. Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma. J Clin Lab Anal. Sep 2017;31(5)doi:10.1002/jcla.22107
8. Al Saleh AS, Parmar HV, Visram A, et al. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. Sep 2020;20(9):596-601. doi:10.1016/j.clml.2020.03.012
9. Lee H, Kong S-Y, Sohn JY, et al. Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma. BioMed research international. 2014;2014(1):145619.
10. Kim DS, Yu ES, Kang K-W, et al. Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. The Korean journal of internal medicine. 2016;32(4):711-721.